This phase III trial evaluates mammographic breast density in participants with hormone
receptor-negative breast cancer enrolled on study A011502. High breast density has been shown
to be a strong risk factor for developing breast cancer and decreasing breast density may
decrease the risk for breast cancer. Participants treated with aspirin may show reduced
breast density on a mammogram.
Intervention
Biospecimen Collection, Screening Mammography
Condition
Breast Carcinoma, Estrogen Receptor Negative, Progesterone Receptor Negative
Investigators
Marie Wood, MD, Daniel M. Anderson, Timothy D. Moore, Bret E. Friday, Deborah W. Wilbur, Marie E. Wood, Subhash C. Sharma, Sunitha Vemulapalli, Maria T. Grosse-Perdekamp, Kent F. Hoskins, Douglas J. Weckstein, Emily G. Robinson, William J. Irvin, Timothy R. Wassenaar, Steven A. Madden, Cynthia M. Vakhariya, Vinay K. Gudena, Mark L. Graham, Jeffrey J. Kirshner, Maria R. Tria Tirona, Arlene A. Gayle, Kathleen J. Yost, Debra M. Prow, Isabelle Bedrosian, Mohamad Kassar, Puja Nistala, John A. Ellerton, Jay W. Carlson, Dan Sotirescu, Robert D. Siegel, Robert J. Behrens, Robert R. Kuske, Sarah J. Sinclair, John M. Schallenkamp, Kelsey E. Larson, David S. Hanson, Dawn L. Hershman, Wendy Y. Chen, Nicholas DiBella, Mukund Nadipuram, Shailaja K. Raj, Sameer Tolay, William E. Richards, M. Bassel Atassi, Wajeeha Razaq, Gijsberta Van Londen, James E. Radford, Susanna Hong, Nibal Saad, Bryan A. Faller, John J. Inzerillo